ER/PR/HER2-positive breast cancer: gallbladder, liver, lung, pleural, and bone metastases after incomplete adjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer. Gallbladder metastasis kept ER/PR/HER2 positivity and Ki-67 >40%; markers supported breast origin.

Metastatic Site: gallbladder, liver, lung/pleura, bone

The patient died 3 years and 10 months after lumpectomy after metastatic ER/PR/HER2-positive breast cancer involved the gallbladder, liver, lungs/pleura, and bones following incomplete adjuvant therapy and loss to surveillance.

PubMed CentralRead more →

Stage IV Invasive Lobular Carcinoma: Nikoo's Patient Story

Patient Info: Nikoo, Female, 40s | Stage IV

Biomarkers: BRCA1/2 negative; PIK3 mutation reported on liquid biopsy

Metastatic Site: Peritoneal/abdominal lining; abdominal lymph nodes

Nikoo had Stage I invasive lobular breast cancer in 2003 and developed Stage IV metastatic recurrence in 2022 after about 19 years. As of October 2025, she was living with metastatic lobular breast cancer, had moved through multiple systemic options, and was participating in a Phase 1 clinical trial.

The Patient StoryRead more →

Stage IIA breast collision tumor: disease-free after surgery and adjuvant therapy

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Two breast tumor parts were ER-positive; one HER2-low/negative and one HER2-positive. BRCA testing was suggested but not done.

Four years after surgery, she remained disease-free after mastectomy, adjuvant chemotherapy, HER2-targeted therapy, and endocrine therapy.

PubMed CentralRead more →

Stage IV Breast Cancer: Dana's Patient Story

Patient Info: Dana, Female, 50s | Stage IV

Metastatic Site: Liver; bones; lymph nodes

As of October 2025, Dana was living with stable Stage IV metastatic breast cancer involving the liver, bones, and lymph nodes, controlled with targeted therapy and hormone blockers while also managing bipolar disorder and treatment-related mental health effects.

The Patient StoryRead more →

HER2-positive invasive lobular breast cancer in a transgender man: disease-free after multimodality care

Patient Info: Anonymized, transgender man, 70+ | Stage III

Biomarkers: HER2-positive invasive lobular breast cancer, ER/PR negative

Nearly 2 years after diagnosis, he remained disease-free while continuing survivorship care and counseling after discontinuing testosterone therapy.

PubMed CentralRead more →

Stage IV Breast Cancer: Maria's Patient Story

Patient Info: Maria, Female | Stage IV

Metastatic Site: Bone (spine, clavicle, rib, thigh bone, scapula);…

Maria initially had a clean PET scan after chemotherapy, surgery, radiation, and targeted/endocrine therapy, but later developed Stage IV metastatic breast cancer involving multiple bone sites, with lung and cervical-region involvement also described. As of September 2025, she remained on treatment and did not have an available clinical trial option.

The Patient StoryRead more →

Breast Cancer: Marissa's Survivor Story

Patient Info: Marissa Coreno, Female, Under 40

Biomarkers: Tumor biomarkers not reported; no apparent genetic predisposition for breast cancer

As of August 2025, Marissa was 31, had no sign of cancer, and remained on estrogen-blocking therapy planned for 10 years after chemotherapy, bilateral mastectomies, reconstruction, radiation, a CDK 4/6 inhibitor pill and a bisphosphonate.

Cleveland ClinicRead more →

Stage IV Breast Cancer: Linda's Patient Story

Patient Info: Linda Norman, Female, 60s | Stage IV

Metastatic Site: Bone: humerus/shoulder region

As of August 2025, Linda was 1 year into treatment for bone-metastatic breast cancer with letrozole, Verzenio, and bone-strengthening infusions; scans showed the tumor had not grown and bone scarring suggested healing.

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage IV Breast Cancer: Suzy's Survivor Story

Patient Info: Suzy, Female | Stage IV

Metastatic Site: Bone

As of July 2025, Suzy was living with de novo Stage IV bone-metastatic breast cancer and had achieved no evidence of active disease after starting targeted treatment in May 2023.

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed CentralRead more →

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Elissa's Patient Story

Patient Info: Elissa, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; no hereditary mutation reported

Metastatic Site: lymph nodes, liver, spine

Elissa had Stage IV HER2-positive metastatic breast cancer with an early strong response to systemic therapy, but she described the disease as long-term and not curative. As of July 2025, she had lived with metastatic breast cancer for about 4 years and had received roughly 5 lines of treatment.

The Patient StoryRead more →

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed CentralRead more →

HER2-Positive Pleomorphic Lobular Breast Cancer in a 43-Year-Old Woman

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive, ER-negative, PR-negative

Postoperative adjuvant treatment continued with HER2-targeted therapy after chemotherapy and radiation.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

HER2-positive breast cancer with metastatic recurrence and complete response to T-DM1

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 IHC 3+ and hormone receptor-negative in primary and metastatic breast cancer; no liver metastases seen.

Metastatic Site: major pectoralis muscle, lung, broncho-hilar lymph…

After complete radiologic response on T-DM1, treatment was stopped after 22 months because of porto-sinusoidal vascular disorder. Seven months later, she remained asymptomatic and under surveillance with no signs of recurrent disease.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-FarberRead more →

Stage IV HER2-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Masters, Female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Chest wall/skin near surgery incision; lymph nodes

As of May 2025, Jennifer had no reported recurrence for several years after Stage IV HER2-positive metastatic breast cancer responded completely to clinical-trial treatment with T-DM1 and neratinib; she continued annual Cleveland Clinic visits and remained active with family and volunteering.

Cleveland ClinicRead more →

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →

Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient StoryRead more →